The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
Open accessThe DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are usually associated with loss of dopaminergic neurons. Loss of substantia nigra neurons and presence of Lewy body inclusions in some of the remaining neurons are the hallmark pathology seen in the final stages of the disease. Attempts to correlate Lewy body pathology to either cell death or severity of clinical symptoms, however, have not been successful. While the pathophysiology of the neurodegenerative process can hardly be explained by Lewy bodies, the clinical symptoms do indicate a degenerative process located at the presynapse resulting in a neurotransmitter deficiency. Recently it was shown that 90% or even more of alpha-synuclein aggregates in DLB cases were located at the presynapses in the form of very small deposits. In parallel, dendritic spines are retracted, whereas the presynapses are relatively preserved, suggesting a neurotransmitter deprivation. The same alpha-synuclein pathology can be demonstrated for PD. These findings give rise to the notion that not cell death but rather alpha-synuclein aggregate-related synaptic dysfunction causes the neurodegeneration. This opens new perspectives for understanding PD and DLB. If presynaptic alpha-synuclein aggregation, not neuronal loss, is the key issue of the neurodegenerative process, then PD and DLB may eventually be treatable in the future. The disease may progress via trans-synaptical spread, suggesting that stem cell transplants are of limited use. Future therapies may focus on the regeneration of synapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD is associated with four cardinal motor symptoms, including tremors, rigidity, bradykinesia, and postural instability, alongside the characteristic shuffling and stooped posture of the “Parkinsonian gait” [46].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“It could be demonstrated that the presence of symptoms may be related to the involvement of defined regions as measured by the occurrence of Lewy bodies [47–49], supporting the observations that the a-synuclein aggregation pathology spreads through the brain involving anatomical structures sequentially [13].”
BackgroundAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“The discovery of mutations in the a-synuclein gene [77, 114, 156] and overexpression of a-synuclein [123] as being associated with Parkinson’s disease or dementia with Lewy bodies (DLB) strengthens the association between protein”
BackgroundParkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 2×
“Tremor at rest, rigidity, akinesia/bradykinesia and postural instability are the four cardinal features in Parkinson’s disease [60].”
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 1×
“association between the frequency and extension of tangles and Ab-plaques and the occurrence of the disease [55, 104], Terry et al.”
BackgroundChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“It was assumed that the cognitive impairment in AD is related to a synaptic failure [121, 124, 130].”
Background
Cited by
Items 101–200 of 664
Mitochondrial Dysfunction andα-Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First?
Zaltieri, M., Longhena, F., Pizzi, M., Missale, C., Spano, P., & Bellucci, A. (2015) · Parkinson's Disease · doi:10.1155/2015/108029 · Cited by 88
ɑ‐Synuclein strains and the variable pathologies of synucleinopathies
Peelaerts, W., & Baekelandt, V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13595 · Cited by 105
Course and risk factors for excessive daytime sleepiness in Parkinson's disease
Zhu, K., van Hilten, J. J., & Marinus, J. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.01.020 · Cited by 96
Glial Control of Synapse Number in Healthy and Diseased Brain
Lee, E., & Chung, W.-S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00042 · Cited by 91
“Abnormal intraneuronal and intraneuritic deposits of fibrillary, α-synuclein aggregates are thought to be the main cause of PD. Aggregates of αsynuclein have been found at presynaptic terminals in PD, resulting in synaptic degeneration (Schulz-Schaeffer, 2010).”
BackgroundNeurochemistry and the non-motor aspects of PD
Ferrer, I., López-Gonzalez, I., Carmona, M., Dalfó, E., Pujol, A., & Martínez, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.019 · Cited by 87
EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology
van der Zande, J. J., Gouw, A. A., van Steenoven, I., Scheltens, P., Stam, C. J., & Lemstra, A. W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00190 · Cited by 88
“It has been suggested that in DLB, not cell death, but rather α-synuclein aggregaterelated synaptic dysfunction is related to clinical symptoms (Schulz-Schaeffer, 2010).”
BackgroundSex effects on brain structure in de novo Parkinson’s disease: a multimodal neuroimaging study
Tremblay, C., Abbasi, N., Zeighami, Y., Yau, Y. H. C., Dadar, M., Rahayel, S., & Dagher, A. (2020) · Brain · doi:10.1093/brain/awaa234 · Cited by 101
Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease
Chouhan, A. K., Guo, C., Hsieh, Y.-C., Ye, H., Senturk, M., Zuo, Z., Li, Y., Chatterjee, S., Botas, J., Jackson, G. R., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0333-4 · Cited by 88
Adult Hippocampal Neurogenesis in Parkinson’s Disease: Impact on Neuronal Survival and Plasticity
Regensburger, M., Prots, I., & Winner, B. (2014) · Neural Plasticity · doi:10.1155/2014/454696 · Cited by 85
Longhena, F., Faustini, G., Spillantini, M. G., & Bellucci, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010141 · Cited by 94
Sorrentino, Z. A., Goodwin, M. S., Riffe, C. J., Dhillon, J.-K. S., Xia, Y., Gorion, K.-M., Vijayaraghavan, N., McFarland, K. N., Golbe, L. I., Yachnis, A. T., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0787-2 · Cited by 85
IQGAP1 regulates NR2A signaling, spine density, and cognitive processes
Gao, C., Frausto, S. F., Guedea, A. L., Tronson, N. C., Jovasevic, V., Leaderbrand, K., Corcoran, K. A., Guzman, Y. F., Swanson, G. T., & Radulovic, J. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1300-11.2011 · Cited by 85
Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease
Wilson, H., Pagano, G., de Natale, E. R., Mansur, A., Caminiti, S. P., Polychronis, S., Middleton, L. T., Price, G., Schmidt, K. F., Gunn, R. N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28064 · Cited by 80
Bae, E.-J., Choi, M., Kim, J. T., Kim, D.-K., Jung, M. K., Kim, C., Kim, T.-K., Lee, J. S., Jung, B. C., Shin, S. J., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00789-x · Cited by 81
Winston, C. N., Chellappa, D., Wilkins, T., Barton, D. J., Washington, P. M., Loane, D. J., Zapple, D. N., & Burns, M. P. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2013.2960 · Cited by 84
Reduced Synaptic Density in Patients with Lewy Body Dementia: An [ 11 C ] UCB‐J PET Imaging Study
Andersen, K. B., Hansen, A. K., Damholdt, M. F., Horsager, J., Skjærbæk, C., Gottrup, H., Klit, H., Schacht, A. C., Danielsen, E. H., Brooks, D. J., et al. (2021) · Movement Disorders · doi:10.1002/mds.28617 · Cited by 84
Characterization of retinal architecture in Parkinson's disease
Chorostecki, J., Seraji‐Bozorgzad, N., Shah, A., Bao, F., Bao, G. W., George, E. B., Gorden, V., Caon, C., Frohman, E. M., Bhatti, M. T., et al. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.05.007 · Cited by 86
van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00388-2 · Cited by 83
Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer's disease
Peraza, L. R., Taylor, J.-P., & Kaiser, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.015 · Cited by 84
“In DLB, the significantly lower functional synchronization might be associated with the presynaptic dysfunction caused by a-synuclein aggregates which are present in the brain cortex, even at early stages of the disease (Kramer and Schulz-Schaeffer, 2007; Schulz-Schaeffer, 2010).”
BackgroundThe Contribution of α-Synuclein Spreading to Parkinson’s Disease Synaptopathy
Longhena, F., Faustini, G., Missale, C., Pizzi, M., Spano, P., & Bellucci, A. (2017) · Neural Plasticity · doi:10.1155/2017/5012129 · Cited by 81
Li, Y., Yang, C., Wang, S., Yang, D. L., Zhang, Y., Xu, L., Ma, L., Zheng, J., Petersen, R. B., Zheng, L., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.274 · Cited by 84
Metabolic connectomics targeting brain pathology in dementia with Lewy bodies
Caminiti, S. P., Tettamanti, M., Sala, A., Presotto, L., Iannaccone, S., Cappa, S. F., Magnani, G., Perani, D., & Initiative, A. D. N. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16654497 · Cited by 85
Stylianou, M., Murphy, N., Peraza, L. R., Graziadio, S., Cromarty, R., Killen, A., O' Brien, J. T., Thomas, A. J., LeBeau, F. E. N., & Taylor, J.-P. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.03.013 · Cited by 79
Axon degeneration and PGC1α-mediated protection in a vertebrate model of α-synuclein toxicity
O’Donnell, K. C., Lulla, A., Stahl, M. C., Wheat, N. D., Bronstein, J. M., & Sagasti, A. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.013185 · Cited by 93
“Aggregate formation in the synapse and axon precedes Lewy body formation and cell death in multiple cell types (Galvin et al., 1999; Orimo et al., 2008; Schulz-Schaeffer, 2010; Nakata et al., 2012).”
BackgroundMechanisms of alpha-synuclein toxicity: An update and outlook
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.10.005 · Cited by 75
Ma, L., Yang, C., Zhang, X., Li, Y., Wang, S. L., Zheng, L., & Huang, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.003 · Cited by 80
Can neuroimaging predict dementia in Parkinson’s disease?
Lanskey, J. H., McColgan, P., Schrag, A. E., Acosta‐Cabronero, J., Rees, G. E., Morris, H. R., & Weil, R. S. (2018) · Brain · doi:10.1093/brain/awy211 · Cited by 84
“This is unsurprising, given that conventional methods rely on loss of volume caused by neuronal death, a relatively late event in Parkinson’s dementia (Schulz-Schaeffer, 2010; Hattori et al., 2012).”
MethodNeuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease
Ferrer, I. (2011) · Parkinson's Disease · doi:10.4061/2011/708404 · Cited by 71
Neurogenesis in Neurodegenerative Diseases: Role of MFG-E8
Cheyuo, C., Aziz, M., & Wang, P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00569 · Cited by 78
“Parkinson’s disease is characterized pathologically by intracellular deposits of α-synuclein and degeneration of neurons (Schulz-Schaeffer, 2010).”
BackgroundRoy, B., & Jackson, G. R. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu011 · Cited by 75
Antibodies against alpha‐synuclein: tools and therapies
Vaikath, N. N., Hmila, I., Gupta, V. R., Erskine, D., Ingelsson, M., & El‐Agnaf, O. M. A. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14713 · Cited by 77
The pathomechanisms underlying Parkinson's disease
Jellinger, K. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.877842 · Cited by 83
Alpha-Synuclein and Lipids: The Elephant in the Room?
Sarchione, A., Marchand, A., Taymans, J.-M., & Chartier-Harlin, M.-C. (2021) · Cells · doi:10.3390/cells10092452 · Cited by 66
“Indeed, it has long been established that aggregated α-syn is a hallmark of synucleinopathies, including the presence of α-syn positive Lewy bodies in the neurons of PD, dementia with Lewy bodies [27] and some variants of Alzheimer’s disease [27,28].”
BackgroundBrain atrophy progression in Parkinson’s disease is shaped by connectivity and local vulnerability
Tremblay, C., Rahayel, S., Vo, A., Morys, F., Shafiei, G., Abbasi, N., Markello, R. D., Gan‐Or, Z., Mišić, B., & Dagher, A. (2021) · Brain Communications · doi:10.1093/braincomms/fcab269 · Cited by 78
“This is consistent with post-mortem evidence that a-synuclein aggregates are mostly located in synapses.(25) Indeed, Lewy neurites, consisting of a-synuclein aggregates in presynaptic terminals, are a hallmark of Parkinson’s disease pathology,(94) and one of the many functions of a-synuclein is to regulate synaptic ho…”
ResultNazarinia, D., Behzadifard, M., Gholampour, J., Karimi, R., & Gholampour, M. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-01984-3 · Cited by 76
Mollenhauer, B., Parnetti, L., Rektorová, I., Kramberger, M. G., Pikkarainen, M., Schulz‐Schaeffer, W., Aarsland, D., Svenningsson, P., Farotti, L., Verbeek, M. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13390 · Cited by 80
“1), 290--317 Table 3 (continued) Study Cases Protein measurements Method Neuropathology Remarks Engelborghs et al. (2008) 100 autopsy-confirmed dementia (46 AD, 9 MXD (n = 9), 3 FTD, 1DLB, 6 PDD, 7 CJD, 1 CJD (Heidenhain variant), 5 VaD, 1 NPH) and 100 C; without autopsy) Ab42, t-tau, p-tau181P Commercially available…”
BackgroundInfluentialSelf-citationThe impact of base excision DNA repair in age-related neurodegenerative diseases
Leandro, G. S., Sykora, P., & Bohr, V. A. (2015) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2014.12.011 · Cited by 72
“The PD neurons show accumulation of Lewy bodies that are proportional to the severity of the symptoms (Schulz-Schaeffer 2010).”
BackgroundThe Human Hippocampus in Parkinson’s Disease: An Integrative Stereological and Proteomic Study
Villar‐Conde, S., Astillero‐Lopez, V., González-Rodríguez, M., Villanueva‐Anguita, P., Saiz‐Sánchez, D., Martínez-Marcos, A., Flores‐Cuadrado, A., & Úbeda‐Bañón, I. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202465 · Cited by 75
“Previous studies support the hypothesis that the pathophysiology of PD begins with the accumulation of (cid:2) -syn microaggregates in presynapses [57].”
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · Cells · doi:10.3390/cells14151161 · Cited by 56
Białecka, M. A., Kurzawski, M., Roszmann, A., Robowski, P., Sitek, E. J., Honczarenko, K., Gorzkowska, A., Budrewicz, S. P., Mak, M., Jarosz, M., et al. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835693f7 · Cited by 80
Retina ganglion cell degeneration in glaucoma: an opportunity missed? A review
Morgan, J. E. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2012.02789.x · Cited by 74
The Role of Glia in Alpha-Synucleinopathies
Fellner, L., & Stefanova, N. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8340-3 · Cited by 68
Epigenetic Changes and Its Intervention in Age-Related Neurodegenerative Diseases
Murshid, N. M., Lubis, F. A., & Makpol, S. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00979-z · Cited by 69
“Lewy bodies, which are related to nerve loss are more abundant in patients with mild and moderate neuronal loss than in those with severe neuronal loss (Schulz-Schaeffer 2010).”
BackgroundGiancola, F., Torresan, F., Repossi, R., Bianco, F., Latorre, R., Ioannou, A., Guarino, M., Volta, U., Clavenzani, P., Mazzoni, M., et al. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12995 · Cited by 74
Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes
Lin, C.-H., Yang, S.-Y., Horng, H.-E., Yang, C.-C., Chieh, J.-J., Chen, H.-H., Liu, B.-H., & Chiu, M.-J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00123 · Cited by 69
“…α-synuclein level is significantly higher in PDD than in PDNC and DLB suggest that the underlying pathophysiology leading to α-synuclein depositions in cortical and nigral neurons in the cognitive dysfunction processes of PD and DLB may be different (Schulz-Schaeffer, 2010; Lin et al., 2017).”
BackgroundHypothesis: A role for EBV-induced molecular mimicry in Parkinson's disease
Woulfe, J., Gray, M. T., Gray, D. A., Muñoz, D. G., & Middeldorp, J. M. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.031 · Cited by 71
“Where?: There is growing appreciation that pathological α-syn aggregation in PD is initiated in neuronal axon terminals and that it then propagates retrogradely toward neuronal cell bodies [79].”
Mayo, M., & Bordelon, Y. M. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1381741 · Cited by 82
Beekes, M., Thomzig, A., Schulz-Schaeffer, W. J., & Burger, R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1324-9 · Cited by 64
Self-citationWatanabe, H., Ono, M., Ariyoshi, T., Katayanagi, R., & Saji, H. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00450 · Cited by 68
Altered Whole-Brain and Network-Based Functional Connectivity in Parkinson's Disease
de Schipper, L. J., Hafkemeijer, A., van der Grond, J., Marinus, J., Henselmans, J. M. L., & van Hilten, J. J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00419 · Cited by 75
“These α-SynA were detected throughout the cortex of Lewy body disease patients and were most dense in the cingulate cortex (5, 49).”
BackgroundLehoczki, A., Fekete, M., Jarecsny, T., Zábó, V., Szappanos, Á., Csípő, T., Lipécz, Á., Major, D., Fazekas‐Pongor, V., Varga, P., et al. (2025) · Nutrients · doi:10.3390/nu17172884 · Cited by 78
“α -Synuclein aggregation is a central pathological mechanism in PD, leading to the formation of Lewy bodies and neurodegeneration [101].”
P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity
Kalogeropulou, A. F., Zhao, J., Bolliger, M. F., Memou, A., Narasimha, S., Molitor, T. P., Wilson, W. H., Rideout, H. J., & Nichols, R. J. (2018) · Biochemical Journal · doi:10.1042/bcj20170699 · Cited by 73
Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease
Glotfelty, E. J., Olson, L., Karlsson, T. E., Li, Y., & Greig, N. H. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764534 · Cited by 63
“ciency that disrupts the surviving DA neuron function [16].”
BackgroundLuo, X., Hou, L., Shi, H., Zhong, X., Zhang, Y., Zheng, D., Tan, Y., Hu, G., Mu, N., Chan, J., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12331 · Cited by 64
“Decreasing levels of a-synuclein in the CSF of DLB patients indicate the accumulation of a-synuclein in the brain, making CSF a-synuclein levels a potential biomarker for Lewyrelated pathologies and discriminating marker between AD and DLB (Schulz-Schaeffer 2010).”
BackgroundMitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson’s Disease?
Faustini, G., Bono, F., Valerio, A., Pizzi, M., Spano, P., & Bellucci, A. (2017) · Genes · doi:10.3390/genes8120377 · Cited by 69
“In this context, the massive amount of insoluble α-synuclein observed at striatal dopaminergic terminals, which is orders of magnitude higher than those detected in LB [9], hints that synapses may even be the primary site of accumulation of α-synuclein.”
BackgroundNeurodegeneration-associated instability of ribosomal DNA
Hallgren, J., Pietrzak, M., Rempała, G. A., Nelson, P. T., & Hetman, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.012 · Cited by 72
Synthesis and in vitro evaluation of α-synuclein ligands
Yu, L., Cui, J., Padakanti, P. K., Engel, L. A., Bagchi, D. P., Kotzbauer, P. T., & Tu, Z. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.06.023 · Cited by 66
Wishart, T. M., Rooney, T. M., Lamont, D. J., Wright, A. K., Morton, A. J., Jackson, M., Freeman, M. R., & Gillingwater, T. H. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002936 · Cited by 60
“For example, published studies have highlighted an important role for synaptic malfunction and degeneration in pre-clinical and early-symptomatic stages of Alzheimer’s disease [2], Parkinson’s disease [3], Huntington’s disease (HD) [4], spinocerebellar ataxia [5], prion diseases [6], lysosomal storage disorders [7] an…”
BackgroundTinaz, S., Lauro, P. M., Ghosh, P., Lungu, C., & Horovitz, S. G. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.12.019 · Cited by 66
Neural stem cells: mechanisms and modeling
Yao, J., Mu, Y., & Gage, F. H. (2012) · Protein & Cell · doi:10.1007/s13238-012-2033-6 · Cited by 71
“The pathogenesis of PD is caused by the accumulation of misfolded alpha-synuclein into the intracellular Lewy bodies (Aarsland et al., 2009; Schulz-Schaeffer, 2010; Vekrellis et al., 2011) and insufficient dopamine expression in neurons in the substantia nigra of the midbrain (Goedert, 2001; Braak…”
BackgroundPotential Role of Epigenetic Mechanism in Manganese Induced Neurotoxicity
Tarale, P., Chakrabarti, T., Sivanesan, S., Naoghare, P. K., Bafana, A., & Krishnamurthi, K. (2016) · BioMed Research International · doi:10.1155/2016/2548792 · Cited by 65
“α-Synuclein has been known to play a significant role in the dopaminergic cell death as observed in Lewy body diseases such as Parkinson’s disease [170, 171].”
Dutta, D., Kundu, M., Mondal, S., Roy, A., Ruehl, S., Hall, D. A., & Pahan, K. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104575 · Cited by 58
“…inclusions (Lewy bodies), mitochondrial dysfunction, and inflammation are the important pathological features of the disease (Alam et al., 1997; Borah and Mohanakumar, 2010; Dexter et al., 1989; GonzalezHernandez et al., 2010; Przedborski, 2004; Schapira et al., 1989; Schulz-Schaeffer, 2010).”
BackgroundMultifunctional role of natural products for the treatment of Parkinson’s disease: At a glance
Rahman, M. M., Wang, X., Islam, M. R., Akash, S., Supti, F. A., Mitu, M. I., Harun-Or-Rashid, M., Aktar, M. N., Kali, M. S. K., Jahan, F. I., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.976385 · Cited by 64
Blennow, K., Biscetti, L., Eusebi, P., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26656 · Cited by 66
Compta, Y., & Révész, T. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202323 · Cited by 64
“presynaptic -synuclein aggregates and the loss of dendritic spines as critical events for neurodegeneration in Lewy-related disorders [41, 42].”
BackgroundCriteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0466-z · Cited by 60
After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders
Huber, K., & Superti‐Furga, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.018 · Cited by 66
Mani, S., Sevanan, M., Krishnamoorthy, A., & Sekar, S. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05551-1 · Cited by 61
“In any case, regardless of the majority of the proof of connections among MPTP and PD, there are contrasts between MPTP models of PD and idiopathic PD with varieties in sickness movement, an intense beginning, and the absence of normal LB development [69].”
BackgroundContribution of Yeast Models to Neurodegeneration Research
Pereira, C., Bessa, C., Soares, J., Leão, M., & Saraiva, L. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/941232 · Cited by 55
Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences
Koziorowski, D., Figura, M., Milanowski, Ł., Szlufik, S., Alster, P., Madetko‐Alster, N., & Friedman, A. (2021) · Cells · doi:10.3390/cells10030656 · Cited by 63
“Oligomeric soluble forms of α-synuclein, invisible on histopathological examination, seem to play a major role in proteasome and lysosomal mechanisms [96].”
BackgroundLiu, G., Chen, M., Mi, N., Yang, W., Li, X., Wang, P., Yin, N., Li, Y., Yue, F., Chan, P., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.004 · Cited by 60
Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies
Garcia-Esparcia, P., Diaz-Lucena, D., Ainciburu, M., Torrejón-Escribano, B., Carmona, M., Llorens, F., & Ferrer, I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00122 · Cited by 55
“Since synaptic connectivity is reduced in frontal cortex in AD and DLB (Jellinger, 2000; Selkoe, 2002; Hashimoto and Masliah, 2003; Gong and Lippa, 2010; Schulz-Schaeffer, 2010; Ferrer, 2012; de Wilde et al., 2016; Santpere et al., 2017), the possibility of reduced GLT1 expression secondary to decreased synaptic activ…”
BackgroundJellinger, K. A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02028-6 · Cited by 60
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Porciúncula, L. O., Goto‐Silva, L., Ledur, P. F., & Rehen, S. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.674563 · Cited by 59
“Accumulation of α-synuclein generates synaptic dysfunction which leads to neurodegeneration (Schulz-Schaeffer, 2010; Stefanis, 2012).”
BackgroundMitochondrial ATP Synthase is a Target of Oxidative Stress in Neurodegenerative Diseases
Ebanks, B., & Chakrabarti, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.854321 · Cited by 62
“Mutations in the SNCA gene that encodes α-synuclein are also a feature of PD, as the aggregation of the protein leads to the formation of toxic oligomers and fibrils (Schulz-Schaeffer, 2010; Mahul-Mellier et al., 2020).”
BackgroundTarale, P., Daiwile, A. P., Sivanesan, S., Stöger, R. J., Bafana, A., Naoghare, P. K., Parmar, D., Chakrabarti, T., & Krishnamurthi, K. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.10.003 · Cited by 59
Vesicle trafficking and lipid metabolism in synucleinopathy
Fanning, S., Selkoe, D. J., & Dettmer, U. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02177-z · Cited by 60
Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis
Gadhe, L. G., Sakunthala, A., Mukherjee, S., Gahlot, N., Bera, R., Sawner, A. S., Kadu, P., & Maji, S. K. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106736 · Cited by 58
Miñones-Moyano, E., Friedländer, M. R., Pallarès-Albanell, J., Kagerbauer, B., Porta, S., Escaramís, G., Ferrer, I., Estivill, X., & Martí, E. (2013) · RNA Biology · doi:10.4161/rna.24813 · Cited by 61
Marín, R., Fabelo, N., Martín, M. V., Garcia‐Esparcia, P., Ferrer, I., Quinto‐Alemany, D., & Díaz, M. L. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.027 · Cited by 62
Onset and evolution of anxiety in Parkinson's disease
Zhu, K., van Hilten, J. J., & Marinus, J. (2016) · European Journal of Neurology · doi:10.1111/ene.13217 · Cited by 59
Peraza, L. R., Colloby, S. J., Firbank, M., Greasy, G. S., McKeith, I. G., Kaiser, M., O'Brien, J. T., & Taylor, J. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4342 · Cited by 57
Accumulation of α-Synuclein Triggered by Presynaptic Dysfunction
Nakata, Y., Yasuda, T., Fukaya, M., Yamamori, S., Itakura, M., Nihira, T., Hayakawa, H., Kawanami, A., Kataoka, M., Nagai, M., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2220-12.2012 · Cited by 61
“In human DLB brains, 90% of Syn aggregates are located in the presynaptic terminals in the form of small deposits (Neumann et al., 2002; Kramer and Schulz-Schaeffer, 2007; Schulz-Schaeffer, 2010).”
BackgroundInfluentialMamais, A., Raja, M., Manzoni, C., Dihanich, S., Lees, A., Moore, D., Lewis, P. A., & Bandopadhyay, R. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.05.017 · Cited by 52
“Furthermore, it has also been suggested that dopaminergic neurodegeneration can be a result of α-synuclein aggregate-related synaptic dysfunction through a dying back phenomenon initiated in the basal ganglia (Schulz-Schaeffer, 2010).”
BackgroundAmyloid Oligomer Neurotoxicity, Calcium Dysregulation, and Lipid Rafts
Malchiodi‐Albedi, F., Paradisi, S., Matteucci, A., Frank, C., & Diociaiuti, M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/906964 · Cited by 62
Garcia-Esparcia, P., López-González, I., Grau-Rivera, O., García-Garrido, M. F., Konetti, A., Llorens, F., Zafar, S., Carmona, M., del Rio, J. A., Zerr, I., et al. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00089 · Cited by 53
Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases
Myeku, N., & Duff, K. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.11.006 · Cited by 62
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 60
BDNF / TrkB activators in Parkinson's disease: A new therapeutic strategy
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., AlAseeri, A. A., Alruwaili, M., Saad, H. M., & Batiha, G. E. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18368 · Cited by 58
Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson’s Disease?
Schulz‐Schaeffer, W. (2015) · Biomolecules · doi:10.3390/biom5031467 · Cited by 63
“Only a small percentage of -synuclein aggregates in Parkinson’s disease are deposited in the form of Lewy bodies [45].”
BackgroundSelf-citationThe Systemic Synuclein Sampling Study: Toward a Biomarker for Parkinson’s Disease
Visanji, N. P., Mollenhauer, B., Beach, T. G., Adler, C. H., Coffey, C. S., Kopil, C., Dave, K. D., Foroud, T., Chahine, L. M., Jennings, D. L., et al. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0366 · Cited by 57
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
van Steenoven, I., van der Flier, W. M., Scheltens, P., Teunissen, C. E., & Lemstra, A. W. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0537-5 · Cited by 55
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Liu, J., Xu, F., Nie, Z., & Shao, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.570658 · Cited by 55
BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease
Białecka, M. A., Kurzawski, M., Roszmann, A., Robowski, P., Sitek, E. J., Honczarenko, K., Mak, M., Deptuła-Jarosz, M., Gołąb-Janowska, M., Droździk, M., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2013.12.051 · Cited by 54
Vacchi, E., Kaelin‐Lang, A., & Melli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145030 · Cited by 56
Lang, Y., Li, Y., Yu, H., Lin, L., Chen, X., Wang, S., & Zhang, H. (2020) · Aging · doi:10.18632/aging.103028 · Cited by 52
Gold and silver nanoparticles in Alzheimer's and Parkinson's diagnostics and treatments
Scarpa, E., Cascione, M., Griego, A., Pellegrino, P., Moschetti, G., & Matteis, V. D. (2023) · Ibrain · doi:10.1002/ibra.12126 · Cited by 53
“24 The main therapy for PD is levodopa (L ‐ 3,4 ‐ dihydroxyphenylalanine or L ‐ dopa), FIGURE 1 Schematic representation of cognitive decline in Alzheimer's disease.”
Synapsin III is a key component of α‐synuclein fibrils in Lewy bodies of PD brains
Longhena, F., Faustini, G., Varanita, T., Zaltieri, M., Porrini, V., Tessari, I., Poliani, P. L., Missale, C., Borroni, B., Padovani, A., et al. (2018) · Brain Pathology · doi:10.1111/bpa.12587 · Cited by 52
Mohapatra, P., Gopikrishnan, M., Doss, C. G. P., & Chandrasekaran, N. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s442520 · Cited by 54
Metadata
- Authors
- Schulz-Schaeffer, W. J.
- Venue
- Acta Neuropathologica
- Published
- 2010-06-20
- Volume
- 120
- Issue
- 2
- Pages
- 131-143
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC2892607
- OpenAlex
- W2033827101
- Cited by
- 627
- References
- 165
- Citations by year
- 2026: 38 · 2025: 51 · 2024: 45 · 2023: 24 · 2022: 43 · 2021: 48 · 2020: 48 · 2019: 41 · 2018: 40 · 2017: 35 · 2016: 36 · 2015: 29 · 2014: 41 · 2013: 36 · 2012: 35
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Funders
- Volkswagen Foundation (ZN 2168)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- alpha-synuclein aggregation, Lewy bodies, dementia with Lewy bodies, Parkinson's disease, Parkinson's disease dementia, presynaptic dysfunction, synaptic pathology, neurotransmitter deficiency, neurodegeneration, trans-synaptic spread, stem cell transplantation, synapse regeneration
- MeSH terms
- Animals, Brain, Parkinson Disease, Synapses, Lewy Body Disease, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.